Coverage of Addiction Treatment
نویسنده
چکیده
Consider these facts: An often-debilitating brain disease afflicts millions of Americans. This disease is one of the country's greatest killers. Its victims frequently suffer from depression and many physical ailments, and often become unable to work effectively. The disease costs the U.S. economy hundreds of billions of dollars annually-more than cancer, more than heart disease.' Fortunately, although no cure exists, medical treatment can enable recipients to live normal, healthy, and productive lives. Treatment is cheap compared to many other common medical procedures and is highly cost-effective.2 Now consider this: For the vast majority of victims of this disease, effective treatment is inaccessible. Most health insurance plans either do not cover it or put a variety of limits on coverage that do not apply to other diseases. Unless they can pay out of pocket, victims cannot get the treatment they need. To make matters worse, they are often told that their condition is not a real disease, or that it is their fault, or that suffering from it makes them a criminal. The disease is drug and alcohol addiction, and the facts are real. Ubiquitous benefit caps on insurance coverage of substance abuse treatment put effective recovery out of reach for most addicts. In this Note, I assess the nature of this problem and some possible ways to address it. The general principle that I advocate is substance abuse treatment parity, which means that insurance plans should provide coverage for addiction treatment that is equivalent to that provided for analogous conditions. In some cases, failure to provide such parity should be considered illegal disability discrirmintion on the part of employers and insurers. Moreover, new laws should be adopted to require insurance parity explicitly.
منابع مشابه
TRICARE; removal of the prohibition to use addictive drugs in the maintenance treatment of substance dependence in TRICARE beneficiaries. Final rule.
The Department of Defense (DoD) is publishing this final rule to remove the exclusion of drug maintenance programs and allow TRICARE coverage of the substitution of a therapeutic drug, with addictive potential, for a drug of addiction when medically necessary and appropriate as part of a comprehensive treatment plan for an individual with substance use dependence. The current regulation prohibi...
متن کاملSpatial analysis and Localization of Selected Pharmacies Distribution of Agonist Drugs for Addiction Treatment Clients in Substance Abuse centers with GIS
Field of study and Goals: The provision of medical services and the distribution of agonist drugs in substance abuse treatment centers has led to a lack of attention to patients' treatment plans and a greater focus on drug distribution. In order to separate health and pharmaceutical services that are provided for opioid addicts in drug addiction treatment centers, a study has been designed with...
متن کاملPayer Policy Behavior Towards Opioid Pharmacotherapy Treatment in Ohio
OBJECTIVE Few studies examine how payers address the need for improved access to pharmacotherapy for opioid use disorders and the influence of environmental variables on access to opioid agonist and antagonist medications. METHOD The 52 Ohio Addiction Drug Abuse and Mental Health Services (ADAMHS) Boards that disburse funds for treatment services for the uninsured and underinsured were survey...
متن کاملWhy should addiction medicine be an attractive field for young physicians?
AIMS The clinical practice and science of addiction are increasingly active fields, which are attracting professionals from diverse disciplines such as psychology and neurobiology. Our scientific knowledge of the pathophysiology of addiction is rapidly growing, along with the variety of effective treatments available to clinicians. Yet, we believe that the medical specialties of addiction medic...
متن کاملState policy influence on the early diffusion of buprenorphine in community treatment programs
BACKGROUND Buprenorphine was approved for use in the treatment of opioid dependence in 2002, but its diffusion into everyday clinical practice in community-based treatment programs has been slow. This study examines the net impact of efforts by state agencies, including provision of Medicaid coverage, on program-level adoption of buprenorphine as of 2006. METHODS Interviews were conducted wit...
متن کامل